Astrazeneca Pharma India Ltd
AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap BSE Allcap
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
16 Jan - One-on-one investor meetings Jan 21, 2026 with Satish Bhatt, Tejas Trivedi and ICICI Prudential AM.
-
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015
16 Jan - Final income-tax assessment order dated Jan 16, 2026; Rs.11.88 crore proposed adjustment; company to appeal to ITAT.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
16 Jan - RTA certificate dated Jan 6, 2026 confirming compliance with SEBI Regulation 74(5).
-
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Appointment Of Senior Management Personnel
9 Jan - AstraZeneca India appoints Aditi Mehta (Director–Oncology) and Nitin Bindal (Director–Institutional), effective Jan 12, 2026.
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulation, 2015
17 Dec 2025 - AstraZeneca received CDSCO permission to import/sell Datverzo (Datopotamab Deruxtecan) for HR+/HER2- metastatic breast cancer.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from bse
Concalls
-
Aug 2025TranscriptPPT
-
Aug 2024Transcript PPT
-
Aug 2023Transcript PPT
-
Aug 2022Transcript PPT
-
Aug 2021Transcript PPT
-
Sep 2020TranscriptPPT
-
Aug 2020Transcript PPT
-
Jun 2020TranscriptPPT
-
Dec 2019TranscriptPPT
-
Jul 2019TranscriptPPT
-
Sep 2018TranscriptAI SummaryPPT
Part of AstraZeneca UK plc
The company is promoted by AstraZeneca plc, a multinational pharmaceutical and biotechnology company headquartered in England. It has a diverse portfolio in various disease areas and has been successful in developing and manufacturing the Oxford-AstraZeneca COVID-19 vaccine. AstraZeneca Pharmaceuticals AB holds 75% of the company's shareholding.[1] [2]